METOLAZONE | A076466 | SANDOZ INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consultant Services FDA-2015-P-3540 · 5 docket documents Lachman Consultant Services, Inc. filed this citizen petition on behalf of a client requesting that the FDA determine whether UCB Inc.'s ZAROXOLYN (metolazone) Tablets, 10 mg, approved under NDA 017386, were voluntarily withdrawn for safety or effectiveness reasons, and if not, to designate an appro | 505(q) | 2015-10-09 | Withdrawn | Lachman Consultant Services |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.3886
per ea
Lowest NADAC/Unit
$0.2945
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00185560001METOLAZONE 10 MG TABLET | $0.3886 | EA | Generic | — | 2026-06-17 |
| 00185005501METOLAZONE 5 MG TABLET | $0.2945 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.